Drug intelligence / Profile preview

GAGbodies

Development stage: Unknown
Lead developer: Antagonis Biotherapeutics
Modality: Recombinant Proteins and Enzymes

Overview

GAGbodies are a novel class of biologic drugs developed by Antagonis. They are designed to selectively protect glycans (complex carbohydrates on cell surfaces) from participating in chemokine-mediated processes. By targeting and shielding specific glycans, GAGbodies modulate interactions between chemokines and their glycan ligands, potentially altering immune cell trafficking or inflammatory responses. This approach represents a new modality for intervening in diseases where glycan-chemokine interactions play a pathogenic role[8].

Brand names: GAGbodies
Other names: GAGbodies

Beyond the preview

Go deeper on GAGbodies.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAGbodies.

Explore the full profile